IMRX
USDImmuneering Corporation Class A Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.470
Kõrge
$1.490
Madal
$1.430
Maht
0.00M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
52.5M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.20M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.